Cargando…

Negative feedback regulation of the ERK1/2 MAPK pathway

The extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) signalling pathway regulates many cellular functions, including proliferation, differentiation, and transformation. To reliably convert external stimuli into specific cellular responses and to adapt to env...

Descripción completa

Detalles Bibliográficos
Autores principales: Lake, David, Corrêa, Sonia A. L., Müller, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075022/
https://www.ncbi.nlm.nih.gov/pubmed/27342992
http://dx.doi.org/10.1007/s00018-016-2297-8
_version_ 1782461798248611840
author Lake, David
Corrêa, Sonia A. L.
Müller, Jürgen
author_facet Lake, David
Corrêa, Sonia A. L.
Müller, Jürgen
author_sort Lake, David
collection PubMed
description The extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) signalling pathway regulates many cellular functions, including proliferation, differentiation, and transformation. To reliably convert external stimuli into specific cellular responses and to adapt to environmental circumstances, the pathway must be integrated into the overall signalling activity of the cell. Multiple mechanisms have evolved to perform this role. In this review, we will focus on negative feedback mechanisms and examine how they shape ERK1/2 MAPK signalling. We will first discuss the extensive number of negative feedback loops targeting the different components of the ERK1/2 MAPK cascade, specifically the direct posttranslational modification of pathway components by downstream protein kinases and the induction of de novo gene synthesis of specific pathway inhibitors. We will then evaluate how negative feedback modulates the spatiotemporal signalling dynamics of the ERK1/2 pathway regarding signalling amplitude and duration as well as subcellular localisation. Aberrant ERK1/2 activation results in deregulated proliferation and malignant transformation in model systems and is commonly observed in human tumours. Inhibition of the ERK1/2 pathway thus represents an attractive target for the treatment of malignant tumours with increased ERK1/2 activity. We will, therefore, discuss the effect of ERK1/2 MAPK feedback regulation on cancer treatment and how it contributes to reduced clinical efficacy of therapeutic agents and the development of drug resistance.
format Online
Article
Text
id pubmed-5075022
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-50750222016-11-04 Negative feedback regulation of the ERK1/2 MAPK pathway Lake, David Corrêa, Sonia A. L. Müller, Jürgen Cell Mol Life Sci Review The extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) signalling pathway regulates many cellular functions, including proliferation, differentiation, and transformation. To reliably convert external stimuli into specific cellular responses and to adapt to environmental circumstances, the pathway must be integrated into the overall signalling activity of the cell. Multiple mechanisms have evolved to perform this role. In this review, we will focus on negative feedback mechanisms and examine how they shape ERK1/2 MAPK signalling. We will first discuss the extensive number of negative feedback loops targeting the different components of the ERK1/2 MAPK cascade, specifically the direct posttranslational modification of pathway components by downstream protein kinases and the induction of de novo gene synthesis of specific pathway inhibitors. We will then evaluate how negative feedback modulates the spatiotemporal signalling dynamics of the ERK1/2 pathway regarding signalling amplitude and duration as well as subcellular localisation. Aberrant ERK1/2 activation results in deregulated proliferation and malignant transformation in model systems and is commonly observed in human tumours. Inhibition of the ERK1/2 pathway thus represents an attractive target for the treatment of malignant tumours with increased ERK1/2 activity. We will, therefore, discuss the effect of ERK1/2 MAPK feedback regulation on cancer treatment and how it contributes to reduced clinical efficacy of therapeutic agents and the development of drug resistance. Springer International Publishing 2016-06-24 2016 /pmc/articles/PMC5075022/ /pubmed/27342992 http://dx.doi.org/10.1007/s00018-016-2297-8 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Lake, David
Corrêa, Sonia A. L.
Müller, Jürgen
Negative feedback regulation of the ERK1/2 MAPK pathway
title Negative feedback regulation of the ERK1/2 MAPK pathway
title_full Negative feedback regulation of the ERK1/2 MAPK pathway
title_fullStr Negative feedback regulation of the ERK1/2 MAPK pathway
title_full_unstemmed Negative feedback regulation of the ERK1/2 MAPK pathway
title_short Negative feedback regulation of the ERK1/2 MAPK pathway
title_sort negative feedback regulation of the erk1/2 mapk pathway
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075022/
https://www.ncbi.nlm.nih.gov/pubmed/27342992
http://dx.doi.org/10.1007/s00018-016-2297-8
work_keys_str_mv AT lakedavid negativefeedbackregulationoftheerk12mapkpathway
AT correasoniaal negativefeedbackregulationoftheerk12mapkpathway
AT mullerjurgen negativefeedbackregulationoftheerk12mapkpathway